In-Depth Analysis of the Competitive Landscape in the ADC Drug Industry: Moats, Growth Drivers, and Risk Perspectives

In-Depth Analysis of the Competitive Landscape in the ADC Drug Industry: Moats, Growth Drivers, and Risk Perspectives

Core Summary

The Chinese antibody-drug conjugate (ADC) industry is transitioning from a rapid expansion phase to an “innovation integration” phase. This transformation is driven by three core factors: stricter regulations (enhanced NMPA standards and NRDL price negotiations), technological iterations (evolution from 1.0 to 4.0 generation ADC technologies), and global competition (deepening overseas licensing and collaborations). Companies with sustainable competitive advantages must possess a globally validated technology platform, rigorous capital allocation discipline, and cost advantages to cope with medical insurance negotiations. Currently, the industry value chain is differentiated into two key player categories: innovators (capturing drug value through patent platforms) and enablers (CDMO/CROs enjoying industry growth dividends through specialized services). The Chinese ADC market is expected to grow from 800 million yuan in 2022 to 66.2 billion yuan by 2030, with a compound annual growth rate (CAGR) of 72.8%, significantly higher than the global level (30.0%), but intensified competition will systematically eliminate “fast followers” with insufficient differentiation.

1. Industry Framework: Market Size, Regulation, and Value Chain

1. Market Size and Growth Drivers

·Global Market: Expected to grow from 7.9 billion USD in 2022 to 64.7 billion USD by 2030 (CAGR=30.0%), with sales exceeding 10 billion USD in 2023.

·Chinese Market: Expected to grow from 800 million yuan in 2022 to 66.2 billion yuan by 2030 (CAGR=72.8%), increasing its global share from ~1.5% to ~14.7%.

·Core Driving Factors:

oDemand Side: Increasing cancer burden, aging population, improved diagnostic capabilities, and enhanced payment capacity.

oTechnology Side: Optimization of ADC design (antibodies, linkers, payloads) and expansion of indications (from tumors to autoimmune diseases).

2. Regulation and Medical Insurance Access: Moat Selection Mechanism

·NMPA Role Transition: From a follower to a mature regulator, issuing specific guidelines for ADCs (covering CMC, non-clinical, and clinical), raising access thresholds.

·NRDL Negotiation Mechanism:

oAccess Cost: Average price reduction of60% (e.g., Roche’s trastuzumab and AstraZeneca’s trastuzumab deruxtecan included through negotiations in 2024).

oSelection Effect: “Me-too” drugs lacking clinical differentiation or cost control capabilities are systematically eliminated.

oCase: After inclusion in medical insurance, Rongchang Biologics’ vidicizumab saw explosive sales, confirming the logic of “exchanging price for volume”.

3. Value Chain Division: Innovators vs. Enablers

·Innovators (drug developers): Capture value through IP and commercialization, with high risks and binary returns (e.g., Rongchang Biologics, Kelun-Biotech, BaiLi Tianheng).

·Enablers (CDMO/CRO): Capture value through specialized services, with high outsourcing rates (about 70% for ADCs vs. 34% for other biologics), and more stable investment logic (e.g., WuXi AppTec, Tigermed).

2. Moat Analysis Framework: Four Dimensions and Technological Evolution

1. Moat Dimension Definition (based on Morningstar framework adjustments)

·Intangible Assets: Patent portfolios (not single molecule patents), proprietary technology platforms (e.g., BaiLi Tianheng HIRE-ADC), clinical data, and regulatory approvals (e.g., breakthrough therapy).

·Switching Costs: Physician/patient usage habits (for innovators), production process transfer difficulty (for CDMO client lock-in).

·Cost Advantages: Production scale (e.g., Kelun Pharmaceutical), process innovation, and experience curve (yield improvement).

·Network Effects and Effective Scale: Relatively weak in the ADC industry, but KOL networks can consolidate market position.

2. Technological Evolution: From 1.0 to 4.0 Generation ADCs

·Core Design Elements:

oLinker Technology: Balancing blood circulation stability and tumor cell lysis efficiency (site-specific conjugation technology improves DAR uniformity).

oPayloads: Shifting from microtubule inhibitors to DNA damaging agents (emphasizing the “bystander effect”).

oAntibody Engineering: Bispecific ADCs (e.g., BaiLi Tianheng BL-B01D1) enhance targeting and resistance overcoming capabilities.

·Platform Comparison:

Company	Platform Name	Key Differentiation	Main Payload	Typical DAR	External Validation
BaiLi Tianheng	HIRE-ADC	EGFRxHER3 bispecific antibody	Topoisomerase I inhibitor	8	BMS collaboration
Kelun-Biotech	OptiDC™	Kthiol site-specific conjugation	Topoisomerase I inhibitor	7.4	Merck collaboration
Rongchang Biologics	In-house ADC platform	Novel HER2 antibody + bystander effect	Microtubule inhibitor (MMAE)	4	Seagen collaboration
DS Pharma	DXd-ADC	Highly efficient DXd payload + bystander effect	Topoisomerase I inhibitor (DXd)	8	Global standard

3. Target Competition Landscape: Red Ocean vs. Blue Ocean

·HER2: The most crowded field, with competition shifting towards “low HER2 expression” (e.g., Rongchang Biologics’ vidicizumab, Hengrui Medicine’s SHR-A1811).

·TROP2: Kelun-Biotech’s sac-TMT (SKB264) approved for lung cancer indications, the world’s first ADC targeting this site.

·Claudin18.2: An emerging blue ocean (high incidence of gastric cancer), with InnoCare’s IBI343 and Rongchang Biologics’ RC118 making inroads.

3. In-Depth Company Analysis: Innovators vs. Enablers

1. Innovators Financial and Moat Comparison

Company	Moat Strength	Core Assets	2023 Revenue (Billion Yuan)	2023 R&D Expenses (Billion Yuan)	Moat Source and Trend
BaiLi Tianheng	Wide	BL-B01D1 (EGFR/HER3 bispecific)	5.62	7.46	Intangible assets (FIC platform + BMS validation), positive trend
Kelun-Biotech	Wide	SKB264 (TROP2 ADC)	19.33	–	Intangible assets (OptiDC™) + cost advantages (parent company), positive trend
Rongchang Biologics	Medium	Vidicizumab (HER2 ADC)	10.83	13.06	Intangible assets (clinical data + Seagen collaboration), stable trend
Hengrui Medicine	Medium	SHR-A1811 (HER2 ADC)	228.20	60.55	Broad R&D + cost advantages, stable trend
InnoCare	Narrow	IBI343 (CLDN18.2 ADC)	–	–	Dependent on single asset potential, stable trend
BaiO Tai	Narrow	BAT8006 (FRα ADC)	–	–	Technology platform pending validation, stable trend

Key Company Analysis:

·BaiLi Tianheng (688506.SH):

oStrategy: Focus on bispecific ADC platform, BMS collaboration (initial payment of 800 million USD + potential 8.4 billion USD) provides global validation and funding.

oFinancial Turning Point: Expected revenue in 20245.823 billion yuan (+900%+), net profit turning positive to3.708 billion yuan.

oMoat: HIRE-ADC platform supports repeatable innovation, with ROIC expected to reach55% (based on BMS transaction).

·Kelun-Biotech (6990.HK)/Kelun Pharmaceutical (002422.SZ):

oStrategy: Relying on OptiDC™ platform + parent company’s production cost advantages, collaborating with Merck (total value over 10 billion USD).

oClinical Advantage: SKB264 reduces mortality risk by47% in Phase III study for TNBC, with global launch for NSCLC indications in 2025.

oFinancial: Expected net profit attributable to the parent company in 20242.936 billion yuan (+19.53%), with ROIC improving to9.2%.

·Rongchang Biologics (688331.SH):

oStrategy: Dual drive of “autoimmunity + tumors”, with vidicizumab being the first domestically listed ADC.

oCommercialization: Medical insurance expansion drives 2023 revenue1.083 billion yuan (+40.26%), but net loss of1.511 billion yuan.

oRisk: Continued cash flow consumption (2023 operating cash flow -1.503 billion yuan), intensified competition in the HER2 field.

·Hengrui Medicine (600276.SH):

oStrategy: Comprehensive layout of ADC targets (10+ in research), with R&D investment intensity29.4% (82.28 billion yuan in 2024).

oInternationalization: Licensing IDEAYA (DLL3 ADC), Merck (CLDN18.2 ADC) to obtain non-dilutive funding.

oFinancial: In 2024, innovative drug revenue is expected to exceed50% (13.892 billion yuan), with ROIC rebounding to12.5%.

2. Representative Enabler: WuXi AppTec (002821.SZ)

·Moat: High switching costs (difficulty in transferring production processes) + technical barriers (combining biologics and organic chemistry).

·Business Model: “Barbell strategy” – mature small molecule business cash flow supports high-growth ADC CDMO business.

·Market Position: ADC projects account for over50% of biopharmaceutical orders, with a global small molecule CDMO share of7.3%.

4. Risk Analysis

1.Technological Disruption Risk: New payloads (e.g., immunomodulators) or conjugation technologies (e.g., antibody-oligonucleotide) may render existing platforms obsolete.

2.Regulatory Tightening Risk: NMPA raises standards for “clinical value”, impacting pipelines with insufficient differentiation.

3.Global Competition Risk: Giants like DS Pharma and Pfizer/Seagen accelerate entry into China, testing local companies’ innovation speed and commercialization capabilities.

4.Cash Flow Risk: Most biotech companies rely on financing (e.g., Rongchang Biologics’ operating cash flow remains negative), and a tightening financing environment may impact R&D progress.

5. Competitive Landscape Summary: Tiered Classification and Basis

Classification	Company	Classification Basis
Leaders	BaiLi Tianheng	FIC bispecific platform validated globally by BMS, outstanding ROIC and growth potential
	Kelun-Biotech	Leading TROP2 ADC globally + collaboration with Merck, synergy of cost advantages and platform capabilities
	WuXi AppTec	Extremely high conversion costs for ADC CDMO, benefiting from industry growth with lower risks than innovative drug companies
Challengers	Hengrui Medicine	Outstanding R&D breadth and internationalization capabilities, but many ADC pipelines face “fast-follow” competition
	Rongchang Biologics	First-mover advantage and commercial validation, but cash flow consumption and competitive pressure coexist
Followers	InnoCare	Dependent on the potential of single assets like IBI343, moat still under construction
	BaiO Tai/Maiwei Biologics/LePu Biologics	Technology platforms pending clinical validation, facing challenges in funding and execution capabilities

Disclaimer: This article is based solely on publicly available information for industry and company analysis and does not constitute any investment advice. Investors should make independent decisions based on their own risk tolerance.